Early-phase pharmaceutical development is defined by uncertainty. Processes are still taking shape, clinical strategies evolve quickly, and decisions made early can have long-term consequences for both the program and the patient.

In this context, manufacturing environments cannot simply be scaled-down versions of late-stage facilities. They must be designed differently — around flexibility, proximity, and people.

At Corealis, our facility was built specifically to support Phase I and II programs. Located within the science hub, it reflects a deliberate choice to operate at human scale, where scientific rigor, collaboration, and responsiveness can coexist within a fully compliant environment.

Why early-phase manufacturing requires a different approach

Phase I and II manufacturing sits at a critical intersection between development and execution. Unlike commercial production, processes are often still being refined. Unlike early research, the expectations for quality, documentation, and regulatory compliance are already high.

• Lorem ipsum dolor sit amet

• Lorem ipsum dolor sit amet

• Lorem ipsum dolor sit amet

This creates a unique tension: teams must move quickly and adapt, while maintaining control, traceability, and confidence in every batch produced.

Facilities designed primarily for scale can introduce distance — between teams, between decisions and data, and between problems and their resolution. In early phases, that distance can slow progress and increase risk.

Our facility was designed to reduce that distance.

Embedded in the science hub

Being located within the science hub connects Corealis to a broader ecosystem of scientific expertise, innovation, and collaboration.

This environment supports continuous learning and exchange — with technology partners, academic institutions, and regulatory stakeholders. It reinforces our commitment to staying current with evolving scientific and regulatory expectations, while remaining grounded in practical manufacturing realities.

For our partners, it means working with a CDMO that is both focused and connected — deeply engaged in early-phase work, yet integrated into a wider scientific community.